Taysha Gene Therapies (TSHA) Cash from Financing Activities (2020 - 2026)

Taysha Gene Therapies has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $711000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $711000.0, up 1467.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $275.4 million (up 259.21% YoY), and the FY2025 annual result was $274.6 million, up 258.08% from the prior year.
• Cash from Financing Activities came in at $711000.0 for Q1 2026 at Taysha Gene Therapies, down from $49.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $216.3 million in Q2 2025 to a low of -$4.2 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is $711000.0 (2026), against an average of $31.8 million.
• Peak annual rise in Cash from Financing Activities reached 136637.86% in 2023, while the deepest fall reached 245.79% in 2023.
• Taysha Gene Therapies' Cash from Financing Activities stood at $41.2 million in 2022, then tumbled by 110.3% to -$4.2 million in 2023, then jumped by 91.6% to -$357000.0 in 2024, then surged by 13981.23% to $49.6 million in 2025, then slumped by 98.57% to $711000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $711000.0 (Q1 2026), $49.6 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.